CN104922299A - 一种预防和治疗糖尿病性视网膜病变的中草药保健口服液 - Google Patents
一种预防和治疗糖尿病性视网膜病变的中草药保健口服液 Download PDFInfo
- Publication number
- CN104922299A CN104922299A CN201510352313.8A CN201510352313A CN104922299A CN 104922299 A CN104922299 A CN 104922299A CN 201510352313 A CN201510352313 A CN 201510352313A CN 104922299 A CN104922299 A CN 104922299A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- oral liquid
- fructus
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 68
- 206010012689 Diabetic retinopathy Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 72
- 239000002994 raw material Substances 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 238000000605 extraction Methods 0.000 claims abstract description 19
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 15
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 15
- 239000001168 astaxanthin Substances 0.000 claims abstract description 15
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 15
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 15
- 210000000582 semen Anatomy 0.000 claims abstract description 15
- 239000009636 Huang Qi Substances 0.000 claims abstract description 14
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 14
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 14
- 238000004821 distillation Methods 0.000 claims abstract description 7
- 238000005516 engineering process Methods 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 37
- 241000411851 herbal medicine Species 0.000 claims description 34
- 230000036541 health Effects 0.000 claims description 28
- 239000000341 volatile oil Substances 0.000 claims description 26
- 230000002265 prevention Effects 0.000 claims description 23
- 238000002560 therapeutic procedure Methods 0.000 claims description 22
- 238000001914 filtration Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 230000001804 emulsifying effect Effects 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 239000011265 semifinished product Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 5
- 108010059892 Cellulase Proteins 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000010009 beating Methods 0.000 claims description 5
- 229940106157 cellulase Drugs 0.000 claims description 5
- 239000006184 cosolvent Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 238000004945 emulsification Methods 0.000 claims description 5
- 229940088598 enzyme Drugs 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 235000008216 herbs Nutrition 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 239000004302 potassium sorbate Substances 0.000 claims description 5
- 229940069338 potassium sorbate Drugs 0.000 claims description 5
- 235000010241 potassium sorbate Nutrition 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 23
- 230000008901 benefit Effects 0.000 abstract description 3
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 235000007516 Chrysanthemum Nutrition 0.000 abstract 1
- 240000005250 Chrysanthemum indicum Species 0.000 abstract 1
- 241000759833 Cornus officinalis Species 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 241000218231 Moraceae Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 241000405911 Rehmannia glutinosa Species 0.000 abstract 1
- 244000042430 Rhodiola rosea Species 0.000 abstract 1
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 244000272459 Silybum marianum Species 0.000 abstract 1
- 235000010841 Silybum marianum Nutrition 0.000 abstract 1
- 244000228451 Stevia rebaudiana Species 0.000 abstract 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 abstract 1
- 230000035622 drinking Effects 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- HLXRWTJXGMHOFN-XJSNKYLASA-N Verbenalin Chemical compound O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000007674 genetic toxicity Effects 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 206010038491 Renal papillary necrosis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- -1 research shows Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有预防和治疗糖尿病性视网膜病变功效的中草药保健口服液,该产品原料配方为1000份保健口服液的中草药原料组成为虾青素5~10份、石决明10~15份、红景天8~12份、川芎10~15份、三七15~20份、桑椹10~13份、赤芍8~12份、五味子10~15份、枸杞10~16份、淫羊藿10~18份、决明子15~20份、菊花10~15份、葛根12~18份、熟地10~15份、当归8~12份、水飞蓟5~10份、丹皮5~10份、山茱萸10~15份、黄芪10~15份、甜叶菊10~15份,采用“超声波辅助浸提+蒸馏挥发油+水煎+醇提”工艺制备。该产品具有预防和治疗糖尿病性视网膜病变功效好、安全无副作用、饮用方便等优势。
Description
技术领域
本发明涉及一种预防和治疗糖尿病性视网膜病变的中草药保健口服液,特别是一种以海洋活性物质和植物中草药为原料制成的保健口服液,属中草药保健领域。
背景技术
糖尿病是一种常见的代谢性疾病,可引起全身组织、多器官的广泛损害。其中糖尿病视网膜病变既是糖尿病严重的并发症之一,又是一种常见的致盲眼病,为世界公认的四大主要致盲眼病之一,其发病率和致盲率呈逐年上升趋势,目前对于该病尚无一种疗效理想的西药或中药产品,因此探索和开发治疗糖尿病视网膜病变的有效药物是必要和紧急。
中草药是我国传统文化的瑰宝,随着人民生活的逐步提高,人们的保健意识逐渐增强,在化瘀通络、益气养阴、止血明目、缓解视疲劳、预防近视等方面的需求日益增加,中草药在该领域保健食品开发过程中占据着先天优势条件。为传承源远流长的中草药文化,满足人民群众对保健的需求,本发明选取具有补气补益、扶正固本、降血糖降血脂等功效的中草药,研制开发具有预防和治疗糖尿病性视网膜病变的中草药保健口服液。
发明内容
为克服现有预防和治疗糖尿病性视网膜病变产品技术的不足,本发明的目的在于提供一种具有预防和治疗糖尿病性视网膜病变保健功效的中草药保健口服液。
本发明上述目的是通过以下技术方案予以实现的:
本发明提供一种预防和治疗糖尿病性视网膜病变的中草药保健口服液,其特征在于: 1000份口服液中中药原料及质量配比为:虾青素5~10份、石决明10~15份、红景天8~12份、川芎10~15份、三七15~20份、桑椹10~13份、赤芍8~12份、五味子10~15份、枸杞10~16份、淫羊藿10~18份、决明子15~20份、菊花10~15份、葛根12~18份、熟地10~15份、当归8~12份、水飞蓟5~10份、丹皮5~10份、山茱萸10~15份、黄芪10~15份、甜叶菊10~15份。
本发明的优选技术方案是:一种预防和治疗糖尿病性视网膜病变的中草药保健口服液,其特征在于:其中药原料及质量配比为:虾青素8份、石决明13份、红景天12份、川芎12份、三七16份、桑椹12份、赤芍10份、五味子14份、枸杞15份、淫羊藿15份、决明子18份、菊花12份、葛根15份、熟地12份、当归10份、水飞蓟7份、丹皮8份、山茱萸13份、黄芪12份、甜叶菊13份。
本发明提供一种预防和治疗糖尿病性视网膜病变的中草药保健口服液,其特征在于通过以下步骤制备:
(1)分拣称量:将所用中草药分拣,去除杂质等,按照上述比例称重;
(2)原料预处理:根据原料特性不同分别进行原料预处理:
①将虾青素、石决明、红景天、川芎、三七、赤芍、五味子、淫羊藿、决明子、菊花、葛根、熟地、当归、水飞蓟、丹皮、山茱萸、黄芪、甜叶菊混合后进行粉碎处理,过40目筛;
②将桑椹、枸杞混合,加入2~3倍纯净水,打浆,然后加入1~2%果胶酶,在40~50℃条件下酶解10~20min;
(3)超声波辅助酶解:原料混合后加入原料质量比3~5倍纯净水,然后加入原料质量比2~3%纤维素酶、1~2%非淀粉多糖酶,在超声波辅助条件下酶解30~60min,酶解温度控制在40~50℃;
(4)离心:离心分离浸提液和中药草残渣;
(5)蒸馏:向中草药残渣中加入3~5倍量的纯净水,收集挥发油8~10h,挥发油单独收集放置,水溶液过滤,与浸提液合并;
(6)挥发油乳化:将收集的挥发油中加入1.5~2.0%的助溶剂吐温-80,加热乳化;
(7)水煎:将蒸馏后的中草药残渣中加入2~3倍量的水,煎煮3次,每次1.5~2h,水煎液与浸提液合并;
(8)减压浓缩:将合并后的水溶液浓缩至1g/ml的清膏,放冷;
(9)醇沉:向清膏中加入95%的乙醇使含醇量达到60~70%,4℃条件下放置48h以上
(10)醇提:向水煎后的中草药残渣中加入4~6倍量的50%乙醇,加热提取2次,提取时间1~1.5h;
(11)合并抽滤:将醇沉后的液体与醇提液合并抽滤;
(12)减压回收:将抽滤液进行减压回收乙醇至无醇味;
(13)混合:趁热向浓缩液中加入乳化好的挥发油,搅拌均匀;
(14)添加辅料:加入0.10~0.15%的山梨酸钾和1~2%的甜味剂,加水搅拌定容;
(15)静置:将口服液半成品常温下静置48h以上;
(16)离心:将口服液半成品3000r/min离心5~10min;
(17)定容分装:将离心后的口服液定容、分装即得口服液成品。
上述甜味剂选用的是木糖醇、低聚异麦芽糖、蜂蜜中的一种或几种的混合物。
本发明海洋活性物质及中药物组合是在传统中医理论和实践指导下精选药方。本发明海洋活性物质及中药组合物中:(1)虾青素是类胡萝卜素的一种,为一种较强的天然抗氧化剂,研究表明,虾青素很容易通过血脑屏障和细胞膜,能有效地防止视网膜的氧化和感光细胞的损伤,尤其是视网膜黄斑变性效果较叶黄素更加显著;(2)石决明是鲍鱼的外壳,主要含碳酸钙.亦含有机质和少量的镁、铁、硅酸盐、硫酸盐、磷酸盐、氯化物和极微量的碘,具有平肝潜阳、清肝明目等功效,常用于头痛眩晕,目赤翳障,视物昏花,青盲雀目等;(3)红景天能改善睡眠、生血活血、抗脑缺氧、抗疲劳、活血止血、清肺止咳、化淤消肿、解热退烧、滋补元气等功效;(4)川芎是伞形科植物川芎的干燥根茎,系治疗头痛之首选药物,常用于月经不调、经闭痛经、产后瘀滞腥痛、症瘕肿块、胸胁疼痛、头痛眩晕、风寒湿痹、跌打损伤、痈疽疮疡等的预防和治疗;(5)三七具有散瘀止血,消肿定痛之功效,主治咯血,吐血,衄血,便血,崩漏,外伤出血,胸腹刺痛,跌仆肿痛;(6)桑椹含有丰富的活性蛋白、维生素A原、B1、B2、PP及C、氨基酸、苹果酸、琥珀酸、酒石酸、胡萝卜素、矿物质钙、磷、铁、铜、锌等成分,具有提高人体免疫力具有延缓衰老美容养颜等多种功效,被医学界誉为“二十一世纪的最佳保健果品”;(7)赤芍具有行瘀、止痛、凉血、消肿等功效,主治治瘀滞经闭、疝瘕积聚、腹痛、胁痛、衄血、血痢、肠风下血、目赤、痈肿、跌扑损伤;(8)五味子含糖类、脂肪油、挥发油、苹果酸、柠檬酸、酒石酸、维生素C等成分,能增强中枢神经系统的兴奋过程,也能加强抑制过程,使其相互平衡,提高大脑皮层的调节作用;能提高工作率,减轻疲劳;能调节血压,增强心脏功能;能兴奋呼吸,并有祛痰、镇咳作用;能促进胆汁分泌、降低肝炎病人血清谷-丙转氨酶,对肝细胞有一定保护作用;能调节胃液分泌,兴奋子宫,以及增进视力、听力,提高皮肤感受器的辨别能力;(9)枸杞是名贵的药材和滋补品,中医很早就有“枸杞养生”的说法《本草纲目》记载:“枸杞,补肾生精,养肝明目安神,令人长寿,具有养肝、滋肾、润肺等功效;(10)淫羊藿具有补肾阳、强筋骨、祛风湿等功效;(11)决明子具有清肝明目、通便的功能,主治高血压、头痛、眩晕、急性结膜炎、角膜溃疡、青光眼、痈疖疮疡等症;(12)菊花性甘、微寒,具有散风热、平肝明目、消咳止痛的功效,用于治疗头痛眩晕、目赤肿痛、风热感冒、咳嗽等病症效果显著,还具有提神醒脑的功效(13)葛根有解肌退热、透疹、生津止渴、升阳止泻之功;常用于表证发热、项背强痛、麻疹不透、热病口渴、阴虚消渴、热泻热痢、脾虚泄泻;(14)熟地又名熟地黄或伏地,属玄参科植物,是一种上好中药材,具有补血滋阴功效,可用于血虚萎黄,眩晕,心悸失眠,月经不调,崩漏等症,亦可用于肾阴不足的潮热骨蒸、盗汗、遗精、消渴等症,是虚证类非处方药药品六味地黄丸主要成分之一;(15)当归具有补血活血,调经止痛,润肠通便等功效,用于血虚萎黄、眩晕心悸、月经不调、经闭痛经、虚寒腹痛、肠燥便秘、风湿痹痛、跌扑损伤、痈疽疮疡;(16)水飞蓟具有清热解毒,保肝、利胆,保脑,抗X射线等功效;(17)丹皮,苦、辛,微寒,归心、肝、肾经,具有清热凉血、活血化淤、退虚热等功效;(18)山茱萸,又名山芋肉、药枣、实枣儿、枣皮、肉枣等,为我国常用名贵中药材,应用历史悠久;以其补力平和、壮阳而不助火,滋阴而不腻膈,收敛而不留邪等特殊功效被历代医学所喜用。据化学分析,山茱萸含有生理活性较强的山茱萸甙、酒石酸、没食子酸、苹果酸、树酯、鞣质和多种维生素等有效成分,具有增强免疫、抗炎、抗菌等药理作用,是中医临床中常用的一味药;(19)黄芪有益气固表、敛汗固脱、托疮生肌、利水消肿之功效。用于治疗气虚乏力,中气下陷,久泻脱肛,便血崩漏,表虚自汗,痈疽难溃,久溃不敛,血虚萎黄,内热消渴,慢性肾炎,蛋白尿,糖尿病等;(20)甜叶菊具有调节血压、软化血管、降低血脂、降血糖、尿糖、抑菌止血、镇痛、减肥养颜、养阴生津、帮助消化,促进胰腺、脾胃功能和清热解毒等功效。
本发明提供一种预防和治疗糖尿病性视网膜病变的中草药保健口服液,其优势在于:一是科学配伍多种中草药,药物组分经辨证配伍,在作用上相互佐助,能有效预防和治疗糖尿病性视网膜病变;二是在口服液的制备过程中采用“超声波辅助浸提+蒸馏挥发油+水煎+醇提”的工艺,充分糅合中草药中的预防和治疗糖尿病性视网膜病变的功能活性成分,提高治疗效果;三是口服液安全无副作用,饮用方便。
本发明提供一种预防和治疗糖尿病性视网膜病变的中草药保健口服液,通过动物试验进行保健口服液的毒理学试验及安全性评价。小鼠急性经口毒性试验结果表明,本保健口服液对小鼠急性经口最大耐受剂量大于高剂量组75mg/kg·bw; 遗传毒性试验小鼠骨髓细胞微核试验和小鼠精子畸形试验两项试验结果均为阴性,表明该保健口服液无致突变作用;由大鼠30d喂养试验可知,大鼠体征行为正常、体态健康、血液及血液生化指标也无异常变化,因此75mg/kg·bw的剂量(人体推荐量的150倍)属于安全剂量;遗传毒性试验和大鼠30d喂养试验结果均为阴性,因此确定本保健饮料属无毒类食品,人可以安全放心食用。
具体实施方式
下面结合实施例对本发明做进一步说明。
实施例1:
一种预防和治疗糖尿病性视网膜病变的中草药保健口服液,通过以下步骤制备:
(1)分拣称量:将所用中草药分拣,去除杂质等,按照每1000份口服液中虾青素8份、石决明13份、红景天12份、川芎12份、三七16份、桑椹12份、赤芍10份、五味子14份、枸杞15份、淫羊藿15份、决明子18份、菊花12份、葛根15份、熟地12份、当归10份、水飞蓟7份、丹皮8份、山茱萸13份、黄芪12份、甜叶菊13份比例称重;
(2)原料预处理:根据原料特性不同分别进行原料预处理:
①将虾青素、石决明、红景天、川芎、三七、赤芍、五味子、淫羊藿、决明子、菊花、葛根、熟地、当归、水飞蓟、丹皮、山茱萸、黄芪、甜叶菊混合后进行粉碎处理,过40目筛;
②将桑椹、枸杞混合,加入2.5倍纯净水,打浆,然后加入1.5%果胶酶,在40~50℃条件下酶解15min;
(3)超声波辅助酶解:原料混合后加入原料质量比4倍纯净水,然后加入原料质量比2.5%纤维素酶、1.5%非淀粉多糖酶,在超声波辅助条件下酶解45min,酶解温度控制在40~50℃;
(4)离心:离心分离浸提液和中药草残渣;
(5)蒸馏:向中草药残渣中加入4倍量的纯净水,收集挥发油9h,挥发油单独收集放置,水溶液过滤,与浸提液合并;
(6)挥发油乳化:将收集的挥发油中加入1.8%的助溶剂吐温-80,加热乳化;
(7)水煎:将蒸馏后的中草药残渣中加入2.5倍量的水,煎煮3次,每次1.8h,水煎液与浸提液合并;
(8)减压浓缩:将合并后的水溶液浓缩至1g/ml的清膏,放冷;
(9)醇沉:向清膏中加入95%的乙醇使含醇量达到60~70%,4℃条件下放置48h以上
(10)醇提:向水煎后的中草药残渣中加入5倍量的50%乙醇,加热提取2次,提取时间1.2h;
(11)合并抽滤:将醇沉后的液体与醇提液合并抽滤;
(12)减压回收:将抽滤液进行减压回收乙醇至无醇味;
(13)混合:趁热向浓缩液中加入乳化好的挥发油,搅拌均匀;
(14)添加辅料:加入0.12%的山梨酸钾和1.5%的木糖醇,加水搅拌定容;
(15)静置:将口服液半成品常温下静置48h以上;
(16)离心:将口服液半成品3000r/min离心8min;
(17)定容分装:将离心后的口服液定容、分装即得口服液成品。
实施例2:
一种预防和治疗糖尿病性视网膜病变的中草药保健口服液,通过以下步骤制备:
(1)分拣称量:将所用中草药分拣,去除杂质等,按照每1000份口服液中虾青素10份、石决明10份、红景天12份、川芎10份、三七20份、桑椹10份、赤芍12份、五味子10份、枸杞16份、淫羊藿10份、决明子20份、菊花10份、葛根18份、熟地10份、当归12份、水飞蓟5份、丹皮10份、山茱萸10份、黄芪15份、甜叶菊10份比例称重;
(2)原料预处理:根据原料特性不同分别进行原料预处理:
①将虾青素、石决明、红景天、川芎、三七、赤芍、五味子、淫羊藿、决明子、菊花、葛根、熟地、当归、水飞蓟、丹皮、山茱萸、黄芪、甜叶菊混合后进行粉碎处理,过40目筛;
②将桑椹、枸杞混合,加入3倍纯净水,打浆,然后加入2%果胶酶,在40~50℃条件下酶解10min;
(3)超声波辅助酶解:原料混合后加入原料质量比5倍纯净水,然后加入原料质量比3%纤维素酶、2%非淀粉多糖酶,在超声波辅助条件下酶解30min,酶解温度控制在40~50℃;
(4)离心:离心分离浸提液和中药草残渣;
(5)蒸馏:向中草药残渣中加入5倍量的纯净水,收集挥发油8h,挥发油单独收集放置,水溶液过滤,与浸提液合并;
(6)挥发油乳化:将收集的挥发油中加入2.0%的助溶剂吐温-80,加热乳化;
(7)水煎:将蒸馏后的中草药残渣中加入3倍量的水,煎煮3次,每次1.5h,水煎液与浸提液合并;
(8)减压浓缩:将合并后的水溶液浓缩至1g/ml的清膏,放冷;
(9)醇沉:向清膏中加入95%的乙醇使含醇量达到60~70%,4℃条件下放置48h以上
(10)醇提:向水煎后的中草药残渣中加入6倍量的50%乙醇,加热提取2次,提取时间1h;
(11)合并抽滤:将醇沉后的液体与醇提液合并抽滤;
(12)减压回收:将抽滤液进行减压回收乙醇至无醇味;
(13)混合:趁热向浓缩液中加入乳化好的挥发油,搅拌均匀;
(14)添加辅料:加入0.15%的山梨酸钾和2%的低聚异麦芽糖,加水搅拌定容;
(15)静置:将口服液半成品常温下静置48h以上;
(16)离心:将口服液半成品3000r/min离心10min;
(17)定容分装:将离心后的口服液定容、分装即得口服液成品。
实施例3:
一种预防和治疗糖尿病性视网膜病变的中草药保健口服液,通过以下步骤制备:
(1)分拣称量:将所用中草药分拣,去除杂质等,按照每1000份口服液中虾青素5份、石决明15份、红景天8份、川芎15份、三七15份、桑椹13份、赤芍8份、五味子15份、枸杞10份、淫羊藿18份、决明子15份、菊花15份、葛根12份、熟地15份、当归8份、水飞蓟10份、丹皮5份、山茱萸15份、黄芪10份、甜叶菊15份比例称重;
(2)原料预处理:根据原料特性不同分别进行原料预处理:
①将虾青素、石决明、红景天、川芎、三七、赤芍、五味子、淫羊藿、决明子、菊花、葛根、熟地、当归、水飞蓟、丹皮、山茱萸、黄芪、甜叶菊混合后进行粉碎处理,过40目筛;
②将桑椹、枸杞混合,加入2倍纯净水,打浆,然后加入1%果胶酶,在40~50℃条件下酶解20min;
(3)超声波辅助酶解:原料混合后加入原料质量比3倍纯净水,然后加入原料质量比2%纤维素酶、1%非淀粉多糖酶,在超声波辅助条件下酶解60min,酶解温度控制在40~50℃;
(4)离心:离心分离浸提液和中药草残渣;
(5)蒸馏:向中草药残渣中加入3倍量的纯净水,收集挥发油10h,挥发油单独收集放置,水溶液过滤,与浸提液合并;
(6)挥发油乳化:将收集的挥发油中加入1.5%的助溶剂吐温-80,加热乳化;
(7)水煎:将蒸馏后的中草药残渣中加入2倍量的水,煎煮3次,每次2h,水煎液与浸提液合并;
(8)减压浓缩:将合并后的水溶液浓缩至1g/ml的清膏,放冷;
(9)醇沉:向清膏中加入95%的乙醇使含醇量达到60~70%,4℃条件下放置48h以上
(10)醇提:向水煎后的中草药残渣中加入4倍量的50%乙醇,加热提取2次,提取时间1.5h;
(11)合并抽滤:将醇沉后的液体与醇提液合并抽滤;
(12)减压回收:将抽滤液进行减压回收乙醇至无醇味;
(13)混合:趁热向浓缩液中加入乳化好的挥发油,搅拌均匀;
(14)添加辅料:加入0.10%的山梨酸钾和1%的蜂蜜,加水搅拌定容;
(15)静置:将口服液半成品常温下静置48h以上;
(16)离心:将口服液半成品3000r/min离心5~10min;
(17)定容分装:将离心后的口服液定容、分装即得口服液成品。
本发明提供一种预防和治疗糖尿病性视网膜病变的中草药保健口服液,不同的中草药性味各异,功效存在着巨大的差异,不同的中草药组合后存在复杂的相互作用关系,且中草药之间的配比比较密切,不同配比也将使君臣佐使关系发生实质性的变化,从而使复合中草药的关系发生实质性改变。本申请通过虾青素、石决明、红景天、川芎、三七、桑椹、赤芍、五味子、枸杞、淫羊藿、决明子、菊花、葛根、熟地、当归、水飞蓟、丹皮、山茱萸、黄芪、甜叶菊等中草药彼此间存在复杂的相互作用关系,合理配比,取得了预料不到的技术效果,使预防和治疗糖尿病性视网膜病变中草药保健口服液的关系发生实质性改变,本申请中草药保健口服液的总抗氧化能力达到523.116±47.84U/mL,改变中草药配比或中草药组成会降低保健口服液的抗氧化能力。根据《保健食品功能学评价程序和检验方法》对本申请产品进行了功能性评价,采用自发性Ⅱ型糖尿病KK/Upj-Ay小鼠模式,对比分析本发明产品对糖尿病视网膜保护作用。试验结果表明:灌胃给药后本发明产品能显著降低血糖及糖化血红蛋白,光镜和电镜结果显著本发明产品可延缓糖尿病小鼠视网膜病变的出现,并具有较好的治疗功效,与模型组、照组相比差异极显著(p<0.01);用自身及组间对照的方法对产品的预防和治疗糖尿病性视网膜病变进行评价,随机将50名糖尿病性视网膜病变患者分为试验组和对照组,连续服用30h后,试验组视网膜病变明显减轻,总有效率93.33%以上,实验前后血、尿、便常规检查及血生化检验指标均正常,证明了本发明产品具有较好的预防和治疗糖尿病性视网膜病变的功效。此外,试验结果表明,改变海洋活性物质和中草药的组成及比例会显著降低产品的功效,结果差异显著(p<0.05)。
以上实施例仅用于说明本发明的技术方案,而非对其进行限制;尽管参照前述实施例对被发明进行了详细的说明,但对于本领域的普通技术人员来说,依然可以对前述实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而对这些修改或者替换,并不使相应技术方案的本质脱离本发明所要求保护的技术方案的精神和范围。
Claims (2)
1.一种预防和治疗糖尿病性视网膜病变的中草药保健口服液,其特征在于制备工艺包括以下步骤:
(1)分拣称量:将所用中草药分拣,去除杂质等,按照每1000份口服液中虾青素5~10份、石决明10~15份、红景天8~12份、川芎10~15份、三七15~20份、桑椹10~13份、赤芍8~12份、五味子10~15份、枸杞10~16份、淫羊藿10~18份、决明子15~20份、菊花10~15份、葛根12~18份、熟地10~15份、当归8~12份、水飞蓟5~10份、丹皮5~10份、山茱萸10~15份、黄芪10~15份、甜叶菊10~15份比例称重;
(2)原料预处理:根据原料特性不同分别进行原料预处理:
①将虾青素、石决明、红景天、川芎、三七、赤芍、五味子、淫羊藿、决明子、菊花、葛根、熟地、当归、水飞蓟、丹皮、山茱萸、黄芪、甜叶菊混合后进行粉碎处理,过40目筛;
②将桑椹、枸杞混合,加入2~3倍纯净水,打浆,然后加入1~2%果胶酶,在40~50℃条件下酶解10~20min;
(3)超声波辅助酶解:原料混合后加入原料质量比3~5倍纯净水,然后加入原料质量比2~3%纤维素酶、1~2%非淀粉多糖酶,在超声波辅助条件下酶解30~60min,酶解温度控制在40~50℃;
(4)离心:离心分离浸提液和中药草残渣;
(5)蒸馏:向中草药残渣中加入3~5倍量的纯净水,收集挥发油8~10h,挥发油单独收集放置,水溶液过滤,与浸提液合并;
(6)挥发油乳化:将收集的挥发油中加入1.5~2.0%的助溶剂吐温-80,加热乳化;
(7)水煎:将蒸馏后的中草药残渣中加入2~3倍量的水,煎煮3次,每次1.5~2h,水煎液与浸提液合并;
(8)减压浓缩:将合并后的水溶液浓缩至1g/ml的清膏,放冷;
(9)醇沉:向清膏中加入95%的乙醇使含醇量达到60~70%,4℃条件下放置48h以上
(10)醇提:向水煎后的中草药残渣中加入4~6倍量的50%乙醇,加热提取2次,提取时间1~1.5h;
(11)合并抽滤:将醇沉后的液体与醇提液合并抽滤;
(12)减压回收:将抽滤液进行减压回收乙醇至无醇味;
(13)混合:趁热向浓缩液中加入乳化好的挥发油,搅拌均匀;
(14)添加辅料:加入0.10~0.15%的山梨酸钾和1~2%的甜味剂,加水搅拌定容;
(15)静置:将口服液半成品常温下静置48h以上;
(16)离心:将口服液半成品3000r/min离心5~10min;
(17)定容分装:将离心后的口服液定容、分装即得口服液成品。
2.根据权利要求1所述一种预防和治疗糖尿病性视网膜病变的中草药保健口服液,其特征在于所述甜味剂选用的是木糖醇、低聚异麦芽糖、蜂蜜中的一种或几种的混合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510352313.8A CN104922299A (zh) | 2015-06-24 | 2015-06-24 | 一种预防和治疗糖尿病性视网膜病变的中草药保健口服液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510352313.8A CN104922299A (zh) | 2015-06-24 | 2015-06-24 | 一种预防和治疗糖尿病性视网膜病变的中草药保健口服液 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104922299A true CN104922299A (zh) | 2015-09-23 |
Family
ID=54109951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510352313.8A Pending CN104922299A (zh) | 2015-06-24 | 2015-06-24 | 一种预防和治疗糖尿病性视网膜病变的中草药保健口服液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104922299A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110236039A (zh) * | 2019-06-14 | 2019-09-17 | 昆明科晔生物技术有限公司 | 一种提神抗疲劳的白香果饮料及其制备方法 |
CN111012818A (zh) * | 2020-01-07 | 2020-04-17 | 佛山科学技术学院 | 一种防近视胶囊及其制备方法 |
US11696593B2 (en) | 2018-08-24 | 2023-07-11 | Bioscience Formulators, LLC | Astaxanthin nutritional compositions and uses |
CN117771322A (zh) * | 2024-02-26 | 2024-03-29 | 云南红青夫生物科技股份有限公司 | 一种缓解视疲劳的虾青素胶囊 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1596914A (zh) * | 2003-09-15 | 2005-03-23 | 徐万富 | 一种治疗由脏腑病所致眼病的药物 |
CN103830495A (zh) * | 2014-02-25 | 2014-06-04 | 韩英 | 一种治疗糖尿病性视网膜病变所致眼底出血的中药组合物及其制备方法 |
-
2015
- 2015-06-24 CN CN201510352313.8A patent/CN104922299A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1596914A (zh) * | 2003-09-15 | 2005-03-23 | 徐万富 | 一种治疗由脏腑病所致眼病的药物 |
CN103830495A (zh) * | 2014-02-25 | 2014-06-04 | 韩英 | 一种治疗糖尿病性视网膜病变所致眼底出血的中药组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
高俊全 等: "《虾青素:健康新世纪的奥秘》", 31 July 2013, 中国医药科技出版社 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11696593B2 (en) | 2018-08-24 | 2023-07-11 | Bioscience Formulators, LLC | Astaxanthin nutritional compositions and uses |
CN110236039A (zh) * | 2019-06-14 | 2019-09-17 | 昆明科晔生物技术有限公司 | 一种提神抗疲劳的白香果饮料及其制备方法 |
CN111012818A (zh) * | 2020-01-07 | 2020-04-17 | 佛山科学技术学院 | 一种防近视胶囊及其制备方法 |
CN117771322A (zh) * | 2024-02-26 | 2024-03-29 | 云南红青夫生物科技股份有限公司 | 一种缓解视疲劳的虾青素胶囊 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102078520B (zh) | 一种治疗神经性头痛的中药制剂及其制备方法 | |
CN104547534A (zh) | 一种具有缓解视疲劳功效的中草药保健口服液 | |
CN106421649A (zh) | 一种治疗脑中风的中药组合物及其制备方法 | |
CN104922299A (zh) | 一种预防和治疗糖尿病性视网膜病变的中草药保健口服液 | |
CN102940785B (zh) | 一种治疗眩晕症的中药组合物 | |
CN102362983A (zh) | 一种治疗眩晕的中药组合物 | |
CN102266532B (zh) | 一种治疗脂肪肝的药物及其制备方法 | |
CN104547778A (zh) | 一种用于超声科防辐射的中药制剂及制备方法 | |
CN104856036B (zh) | 治疗缺铁性贫血的保健药膳及制法 | |
CN105079676A (zh) | 一种治疗脂肪肝的药物及其制备方法 | |
CN104547598A (zh) | 一种治疗神经衰弱的中药制剂及制备方法 | |
CN104524479B (zh) | 一种治疗经前期综合征的中药组合物及其制备方法 | |
CN103784763A (zh) | 治疗肝阳上亢引起偏头痛的中草药 | |
CN103495022B (zh) | 一种辅助治疗艾滋病的中药 | |
CN104940613A (zh) | 一种用于治疗前庭神经炎的中药丸剂及制备方法 | |
CN104857370A (zh) | 一种治疗乳腺癌症的中药组合物 | |
CN104800600A (zh) | 一种治疗高血压的药物 | |
CN104096073A (zh) | 一种治疗男性不育症的中药组合物及其制备方法 | |
CN104606565B (zh) | 预防及治疗眼部疾病的中药胶囊 | |
CN1201811C (zh) | 一种治疗近视眼的中药组合物及制法 | |
CN103735741A (zh) | 一种治疗痛风病的中药组合物 | |
CN103784865A (zh) | 治疗心气不足阴亏肝郁心悸的中草药 | |
CN102526625B (zh) | 一种治疗乙型肝炎的药物及其制备方法 | |
CN102327549A (zh) | 治疗心气不足阴亏肝郁心悸的中草药 | |
CN1593547A (zh) | 一种复方全龟鳖铁皮枫斗养阴胶囊和冲剂制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150923 |
|
WD01 | Invention patent application deemed withdrawn after publication |